Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024

Business Wire 2 days ago

Gilead Sciences Hosts Inaugural Global Health Equity Summit

Accesswire 3 days ago

Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

Business Wire 6 days ago

Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy

Business Wire 10 days ago

Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care

Accesswire 10 days ago

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Business Wire May 9, 2024

Gilead's FOCUS Program Helps Zero In on Early HIV Detection

Accesswire May 9, 2024

Gilead Helps Put African Nation on Path To Eliminate Hepatitis C

Accesswire May 7, 2024

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

Business Wire May 7, 2024

Forbes Has Listed Gilead as One of America's Best Employers for Diversity

Accesswire May 3, 2024

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire April 30, 2024

FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV

Business Wire April 26, 2024

Gilead Sciences Announces First Quarter 2024 Financial Results

Business Wire April 25, 2024

Gilead Sciences Publishes 2023 ESG Impact Report

Accesswire April 18, 2024

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

Business Wire April 8, 2024

Gilead Sciences Champions Equal Pay

Accesswire April 2, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

Business Wire March 28, 2024

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GlobeNewswire March 28, 2024

Winn Awards Help Physicians Solve Healthcare Disparities

Accesswire March 26, 2024

Gilead Sciences Announces Completion of Acquisition of CymaBay

Business Wire March 22, 2024